来自Asarum sieboldii Miq. 的精油 通过调节紧张结和炎症来缓解过敏性鼻炎;网络分析和临床前验证
You Yeon Choi1, Seong Chul Jin1, Seungyob Yi1
1Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee, Republic of Korea.
Journal of ethnopharmacology
|November 9, 2024
概括
来自Asarum sieboldii Miq. 的精油 (ASO) 通过改善紧张的结节和减少鼻炎,有效治疗过敏性鼻炎 (AR). 这项研究支持ASO.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 亚萨鲁姆·西博尔迪米克尔 (Asarum sieboldii Miq.) 是一个植物. 精油 (ASO) 具有传统的抗炎和抗过敏用途.
- 对ASO用于呼吸道过敏炎症的研究缺乏详细的机制研究.
- ASO很容易通过粘膜吸收,使其适合吸入配方.
研究的目的:
- 为了确定Asarum sieboldii Miq.的治疗效果. 精油 (ASO) 用于治疗过敏性鼻炎 (AR),使用生物信息学和网络药理学.
- 阐明ASO在AR上的潜在治疗机制.
- 研究ASO对AR相关途径和症状的影响.
主要方法:
- 网络药理学被用来预测ASO和AR之间的共同基因和途径.
- 在小鼠中使用卵素 (OVA) 和颗粒物10 (PM10) 诱导过敏性鼻炎.
- 通过雾化器对小鼠进行了空气溶液ASO治疗,并评估了他的病理学变化,炎症标志物和过敏症状.
主要成果:
- 网络分析预测了紧密结,细胞亡和TGF-β信号通路是AR病变发生的关键.
- 在小鼠中,ASO治疗改善了与紧结相关的因素 (zonula occludens-1,claudin-1,ocludin,结合粘附分子A).
- ASO减少了鼻上皮质增生,杯状细胞计数,炎症细胞透和过敏症状,同时在体外恢复了紧结的表达.
结论:
- 鼻内雾化ASO可以改善紧张的结节 (TJs) 并缓解AR中的过敏性鼻炎.
- ASO通过减少ROS和促炎细胞因子的产生,显示出显著的抗炎作用.
- 这些发现支持ASO在治疗过敏性鼻炎的潜在制药应用.
更多相关视频
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
411
11:54Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
Published on: January 21, 2018
30.0K
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Antiasthma Drugs: Leukotriene Modifiers
245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
245
Asthma: Pathogenesis and Management
359
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
359
Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353
